Actos Lawsuit News: Bernstein Liebhard LLP Comments on Decline in Actos Sales Since Bladder Cancer Warning

Share Article

The firm is currently investigating Actos lawsuits on behalf of patients who developed bladder cancer, allegedly due to their use of the type 2 diabetes drug.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to hear from long-term Actos users who have since developed bladder cancer.

Takeda Pharmaceuticals Co., which is already facing hundreds of Actos lawsuits filed in the U.S. District Court, Western District of Louisiana, recently reported that sales of the type 2 diabetes drug had declined more than 53% in the third quarter of 2012, compared to the same period last year.* According to a report from, the company said the decline in Actos sales contributed to a 14% drop in net profit for the April-December period.**

“This is not surprising. We continue to hear from long-term Actos users who have since developed bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by the medication.

Actos Bladder Cancer Lawsuit
Actos lawsuits pending in the Western District of Louisiana allege that Takeda Pharmaceuticals and other Defendants concealed their knowledge that Actos could increase the risk for bladder cancer, and failed to provide adequate warnings to consumers and the health care community. According to court documents, the first trial in the federal Actos litigation is scheduled to begin in November 2014, followed by the second trial in July 2015.

The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.*** At the time, Actos was the best-selling diabetes drug in the world, and some experts have speculated that Takeda could eventually face as many as 10,000 Actos bladder cancer lawsuits. While Actos is still available in the U.S., the drug has been pulled from the market in Germany and France due to its association with bladder cancer.****

Since June 2011, a number of studies have confirmed that link, including research published last May in the British Medical Journal which concluded that taking the drug for two years can double the risk of developing bladder cancer. ***** A second study published in the Canadian Medical Association Journal in July 2012 found that patients taking Actos face a 22 percent increased risk of developing bladder cancer. ******

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website